Johnson & Johnson (J&J) company Janssen Pharmaceuticals has partnered with injectable contract development and manufacturing organisation (CDMO) Grand River Aseptic Manufacturing (GRAM) to produce its SARS-CoV-2 vaccine candidate.
Santen Pharmaceutical and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc. ("Eyevance").
Catalent and AstraZeneca have signed an agreement under which the former's subsidiary Catalent Cell & Gene Therapy will offer drug substance manufacturing to the investigational Covid-19 vaccine AZD1222 in the US.
Agilent Technologies has announced an investment of up to $150m to expand its production facility for nucleic acid-based therapeutics in the US.
This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.
Pfizer announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for Covid-19.
Novavax has agreed to grant the Japanese licensing rights to NVX‑CoV2373, a vaccine candidate modified from the genetic sequence of the Covid-19 causing SARS‑CoV‑2 virus, to Takeda Pharmaceutical.
The high performance, inline oxygen sensors from METTLER TOLEDO stand the test of time under challenging operating conditions, whether in the biotechnology, pharmaceutical, brewing or food and beverage industry.
Johnson & Johnson (J&J) announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
Sanofi and GSK today announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.